Vesalius gets to work on €120M Fund III — expect more on women's health, oncology
Vesalius Biocapital, a European VC player that’s bet alongside the corporate venture arms of Novartis, Novo and Merck KGaA, has closed its third fund with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.